Guideline-Based Management of Advanced Prostate Cancer

In our “Guideline-Based Management of Advanced Prostate Cancer” video, our faculty panel delves into this question:

1. What recent guideline updates or data have most influenced your approach to treatment intensification and sequencing in prostate cancer?

Led by the moderator, the panel discusses the role of clinical guidelines in navigating treatment decisions amid real-world constraints, including payer requirements, pharmacy input, and evolving evidence. Faculty highlight National Comprehensive Cancer Network (NCCN) guidelines as a primary reference for justifying treatment choices, particularly in interactions with insurers, whereas American Society of Clinical Oncology (ASCO) guidelines are noted for their clinical applicability and educational value. The American Urological Association guidelines are recognized as especially useful for urologists due to their phenotype-based framework, though they may be less influential in reimbursement discussions. Overall, the discussion emphasizes the importance of readily accessible, trusted guideline resources in daily clinical practice, rather than relying on a single source. Throughout the conversation, the experts offer a comprehensive reflection on the field and the factors that may shape clinicians' approach to care moving forward.

Our next episode, “Workflow in Advanced Prostate Cancer Care,” further explores advanced prostate cancer, highlighting how staffing challenges and workflow gaps can lead to missed care in advanced prostate cancer management. Standardized documentation, clear care ownership, and emerging artificial intelligence tools are highlighted as strategies to improve consistency and patient safety.